Leonardo Tamariz1, Fernando Hernandez2, Aaron Bush3, Ana Palacio2, Joshua M Hare4. 1. Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida; Veterans Affairs Medical Center, Miami, Florida. Electronic address: ltamariz@med.miami.edu. 2. Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida; Veterans Affairs Medical Center, Miami, Florida. 3. Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida. 4. Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida; Division of Cardiology, University of Miami, Miami, Florida.
Abstract
BACKGROUND: Atrial fibrillation (AF) is mediated by oxidative stress, neurohormonal activation, and inflammatory activation. Serum uric acid (SUA) is a surrogate marker of oxidative stress. Xanthine oxidase produces SUA and is upregulated by inflammation and neurohormones. OBJECTIVE: To perform a meta-analysis to evaluate the evidence supporting an association between AF and SUA. METHODS: We searched the MEDLINE database (1966 to 2013) supplemented by manual searches of bibliographies of key relevant articles. We selected all cross-sectional and cohort studies in which SUA was measured and AF was reported. In cross-sectional studies, we calculated the pooled standardized mean difference of SUA between those with AF and those without AF. In cohort studies, we calculated the pooled relative risk with the corresponding 95% confidence interval (CI) for incident AF by using the random effects method. RESULTS: The search strategy yielded 40 studies, of which only 9 met our eligibility criteria. The 6 cross-sectional studies comprised 7930 evaluable patients with a median prevalence of heart failure of 4% (IQR 0%-100%). The standardized mean difference of SUA for those with AF was 0.42 (95% CI 0.27-0.58) compared with those without AF. The 3 cohort studies evaluated 138,306 individuals without AF. The relative risk of having AF for those with high SUA was 1.67 (95% CI 1.23-2.27) compared with those with normal SUA. CONCLUSION: High SUA is associated with AF in both cross-sectional and cohort studies. It is unclear whether SUA represents a disease marker or a treatment target. Published by Elsevier Inc.
BACKGROUND:Atrial fibrillation (AF) is mediated by oxidative stress, neurohormonal activation, and inflammatory activation. Serum uric acid (SUA) is a surrogate marker of oxidative stress. Xanthine oxidase produces SUA and is upregulated by inflammation and neurohormones. OBJECTIVE: To perform a meta-analysis to evaluate the evidence supporting an association between AF and SUA. METHODS: We searched the MEDLINE database (1966 to 2013) supplemented by manual searches of bibliographies of key relevant articles. We selected all cross-sectional and cohort studies in which SUA was measured and AF was reported. In cross-sectional studies, we calculated the pooled standardized mean difference of SUA between those with AF and those without AF. In cohort studies, we calculated the pooled relative risk with the corresponding 95% confidence interval (CI) for incident AF by using the random effects method. RESULTS: The search strategy yielded 40 studies, of which only 9 met our eligibility criteria. The 6 cross-sectional studies comprised 7930 evaluable patients with a median prevalence of heart failure of 4% (IQR 0%-100%). The standardized mean difference of SUA for those with AF was 0.42 (95% CI 0.27-0.58) compared with those without AF. The 3 cohort studies evaluated 138,306 individuals without AF. The relative risk of having AF for those with high SUA was 1.67 (95% CI 1.23-2.27) compared with those with normal SUA. CONCLUSION: High SUA is associated with AF in both cross-sectional and cohort studies. It is unclear whether SUA represents a disease marker or a treatment target. Published by Elsevier Inc.
Authors: A Mantovani; R Rigolon; A Civettini; B Bolzan; G Morani; S Bonapace; C Dugo; G Zoppini; E Bonora; G Targher Journal: J Endocrinol Invest Date: 2017-07-15 Impact factor: 4.256
Authors: A Mantovani; R Rigolon; I Pichiri; M Pernigo; C Bergamini; G Zoppini; E Bonora; G Targher Journal: J Endocrinol Invest Date: 2015-07-16 Impact factor: 4.256